Lex Commentary

The traditional PBM model is under serious pressure. LucyRx and Abarca Health are merging to form a new player serving over 9 million members, betting that employers and health plans are fed up with the big vertically integrated pharmacy middlemen. Fresh reforms passed by Congress this year are adding to the squeeze, and one CEO called it the end of the current PBM model as we know it. The traditional PBM model is said to create incentives that favour large drugmakers and entrenched partners, while smaller competitors, employers, and patients are left at a disadvantage. $PFE historic control of the ATTR-CM market is a case in point: Vyndamax, its signature tafamidis-family drug, is priced at an extortionate $268,000 per year, despite more cost effective alternatives being available on the market. For investors, this points to market share shifting away from the established giants toward leaner, more transparent challengers.

Big money is backing BridgeBio $BBIO. Swiss giant Pictet Asset Management just lifted its stake by nearly 9%, bringing its holding to around $101 million. The vote of confidence comes as the genetic disease focused biotech posted revenue of $194 million last quarter, up a striking 67% from a year ago and well ahead of forecasts. Wall Street is firmly on side too, with 21 Buy ratings and an average price target of $92.90, comfortably above where the stock trades today. Momentum looks strong heading into the second half.

India's pharma stocks just hit a fresh 52 week high, with the Nifty Pharma index climbing nearly 2% as Dr Reddy's $DRREDDY, Cipla $CIPLA, and Ajanta Pharma, $AJANTPHARM, led the charge. The big driver is surging global demand for GLP-1 weight loss and diabetes drugs like semaglutide, where Indian manufacturers are racing to expand capacity as key patents expire. With exports strong and a wave of biosimilar opportunities ahead, the sector is shaping up as one of the standout growth stories for investors to keep on their radar.

AstraZeneca's $AZN miss is huge news in the ATTR-CM market, worth an estimated $15 to $20 billion. The field splits into two approaches: stabilizers, which stop the protein misfolding in the first place, and silencers, which cut its production. AstraZeneca's failed trial has raised fresh questions about the silencer route, since even added on top of standard care it did not show a clear extra benefit. That plays into the hands of the stabilizer makers, and BridgeBio $BBIO looks best placed to capitalise. Its drug Attruby stabilises the protein in 95% of cases, making it a clear market leader and, if the shift toward stabilizers holds, one poised to dominate. No surprise $BBIO jumped 15% on the news.

$ALEMBIC acquires 45% stake in newly formed Canadian entity (17989377 Canada Inc.) alongside Difgen Holdings LLC (45%) to develop, commercialize, and distribute pharma products in Canada. The joint venture positions Alembic for market entry without full acquisition risk. Shareholding split: Alembic 45%, Difgen 45%, others 10%. Canadian expansion play for a mid-cap Indian generic pharma name.

$PFE marketed Depo-Provera for decades as "convenient" birth control without adequately warning about meningioma risk despite research dating back years. Prolonged use of the injectable contraceptive Depo-Provera is associated with a 5.55 times higher risk of developing an intracranial meningioma compared to non-users (BMJ 5.55 risk). Women claim they would have chosen alternatives if warned. FDA added warning December 2025, admission Pfizer knew. June 24-26 Daubert hearing determines if 5,500+ plaintiffs can prove it. Marketing claims outpacing evidence. Again. $PFE's compliance culture problem extends beyond Vyndamax.

Agentic AI in pharma marketing could unlock $450B in value by 2028, per Capgemini. 69% of executives plan agent deployment in marketing by year's end. The pitch: AI agents autonomously execute multi-step tasks across fragmented CRM, events, and claims data silos to personalize HCP engagement at scale. The reality depends entirely on "AI-ready data" and regulatory guardrails around claims queries. Execution risk is high, which signals that agentic marketing in pharma presents risks which are unaccounted for. capgemini.com/insights/exper…

$BBIO's infigratinib delivers the strongest Phase 3 growth data ever reported in achondroplasia. Children treated by PROPEL 3 grew 5.96 cm/year vs 4.22 cm placebo, a 2.1 cm advantage. This is the first statistically significant body proportionality improvement in any achondroplasia trial. And notably, there were zero serious adverse events and zero discontinuations. First-in-class oral therapy for pediatric achondroplasia. $BBIO is now managing three near-term regulatory catalysts simultaneously (infigratinib, encaleret, BBP-418). Strong buy signal for $BBIO

$POLB secures European patent grant for POLB 001, a p38 MAPK inhibitor for cancer immunotherapy-induced Cytokine Release Syndrome (CRS). European protection follows Australian grant (March 2026) and Canadian grant (May 2026). TOPICAL trial interim data expected summer 2026. Patent strengthens IP portfolio across world's largest pharmaceutical market. The patent grant materially strengthens POLB 001's attractiveness to potential partners. For biotech investors, this demonstrates how IP de-risking in early clinical stages inflates valuation points ahead of clinical catalysts meant to speed up/improve clinical trials, particularly in partnership-dependent programs where IP clarity matters.

The FTC's action against the Big Three PBMs exposes a structural vulnerability in $PFE business model that investors have underpriced. For decades, $PFE leaned on PBM rebate leverage to secure pricing power and formulary access for blockbusters like Lipitor, Viagra, Eliquis, Ibrance, and Vyndamax. The mechanism was simple: inflate list prices, negotiate steep rebates to win formulary placement, and bank the margins. That leverage is now collapsing. The FTC has reached settlements with each of the Big Three, forcing greater transparency into their pricing and formularies. The net effect will be to curb the rebate tool that has long underpinned Pfizer's pricing power. Most exposed is the Vyndaqel tafamidis family, including Vyndamax, the ATTR-CM franchise that accounted for 10% of Pfizer's global revenues. Erosion of its most profitable asset carries serious implications. It is time investors priced this in.

This is a game changer for BridgeBio $BBIO. Sixth Street and KKR $KKR have just provided the company $1 billion in preferred equity, one of the biggest biotech financings all year, and the vote of confidence is impossible to ignore. The deal converts at around $138 per share, nearly double $BBIO's current stock price. After 5 years, the conversion price will exceed $150, a clear endorsement of the stock's long-term potential by two of Wall Street's giants. As for $BBIO, the sums put forward by Sixth Street and $KKR is transformational. Today's investment will unlock $BBIO's impressive drug pipeline and accelerate the company's roll out of its impressive portfolio.

$JNJ expands Imaavy label into warm autoimmune hemolytic anemia. Phase 2/3 trial showed durable hemoglobin response vs. placebo in 115 adults. WAIHA is rare, unmet need with no approved treatments. Data to be presented at European Hematology Association meeting. Separate story: Beren secures $300M (debt + equity) to back adrabetadex launch for infantile-onset Niemann-Pick disease. FDA decision expected mid-November. Label expansions + rare disease financing = de-risking across portfolio.

$ELTX crashes 73% after Phase 2 AMPLIFY-7P pancreatic cancer study misses primary endpoint. ELI-002 7P failed to achieve disease-free survival in the intent-to-treat population, though the company attributed the miss to imbalanced baseline patient characteristics (19% vs 10% R1 resection rates between arms). But post-hoc R0-resected subgroup analysis shows 23.8-month median DFS vs 12.8-month observation (84% of trial). Stock down, company advancing refined Phase 3 for R0-only population. Cash runway into Q4 2026. High-risk pivot.

Texas AG sues Eli Lilly, $LLY, for bribing providers with "free nurses" to prescribe Mounjaro/Zepbound. This is the provider-side version of what PBMs do with rebates. Manufacturers pay intermediaries (providers or PBMs) for preferential placement. $PFE Vyndamax (tafamidis), its best selling drug, secured patent extension to 2031 via settlements, but that buys time only if formulary access survives. PBM exclusions, provider kickback schemes, copay assistance blocking, regulators dismantling the entire quid pro quo architecture. Pfizer's margin model is collapsing across every dimension.

Sigma Healthcare, $ASXSIG, walks away from Boots. Australian pharmaceutical wholesaler Sigma Healthcare has withdrawn from discussions over a possible acquisition of UK pharmacy chain Boots, saying a deal valued at $10bn would not align with its strategy. Stock up 8% on the news. The signal: Sigma concluded a $10B deal wouldn't meet strategic and capital investment objectives. It remains committed to UK growth via smaller, targeted platforms (like Greenlight Healthcare stake). Disciplined capital allocation over mega-deal chasing.

BridgeBio Pharma, $BBIO, now worth $13.31 billion, graduated from the Russell 2000 to the Russell 1000 at the June 26, 2026 reconstitution, capping a 75% one-year return to around $67.86. Why it matters: most of the Russell indexes' $12.2 trillion in benchmarked assets sits in the Russell 1000, so graduation opens BBIO to a far larger pool of institutional capital. Small-cap funds will trim as the stock leaves their universe, while large-cap and broad-market funds add it, expanding institutional ownership over time. The index move can create a timing opportunity. Reconstitution typically brings 3-5 days of volatility around June 26, a technical flow rather than a fundamental signal, and any dip into that date is the kind of entry point active investors look to use rather than read as deterioration. Momentum supports the case: Q1 2026 revenue of $194.5 million beat H.C. Wainwright's $167.8 million forecast, lifting its target to $110.

India has set a target of $50 billion in pharmaceutical exports by 2030, up from roughly $30 billion now, anchored in quality, innovation, regulatory excellence and market diversification. Commerce Secretary Rajesh Agrawal noted India runs more than 10,500 manufacturing units and produces over 60,000 generic brands across 60 therapeutic categories, with more than 60% of exports already going to highly regulated markets. The domestic story is material too: a $60 billion market projected to reach $130 billion by 2030. India ranks third globally by volume but only 11th by export value, a gap innovation capacity could close. The transition from generics to innovation is where investors should focus. Biosimilar exports, now $0.8 billion, are set to grow as players expand a 40-plus product pipeline, though India holds under 5% of the global market. Specialty generics and biosimilars carry 3-5x the margin of bulk generics, so the value inflection depends on mix shift, not just volume.

The IPO window for clinical-stage oncology biotech just opened wider. $PBLS Parabilis Medicines priced its IPO at $20 per share, raising roughly $670 million, plus a $75 million private placement backed by Regeneron. That breaks the prior biotech IPO record of $625 million set by Kailera Therapeutics in April 2026. Trading began on Nasdaq today under PBLS, pricing above the guided $17-$19 range, with share count expanded from 25 to 33.3 million. Why it matters: lead asset zolucatetide (FOG-001), a beta-catenin inhibitor, heads to phase 3 in desmoid tumours in H1 2027. Phase 1/2 data showed tumour reductions in 100% of patients and a 74% objective response rate, including in GSI-resistant patients, plus early signals in familial adenomatous polyposis. Kailera's April raise flagged appetite for obesity; Parabilis shows it now extends to early-stage oncology with rare-disease validation and clear pivotal-trial paths.

$PFE Humira faces a structural challenge in 2026, when PBMs removed it from formularies in favor of private-label biosimilars. For years, Humira's commercial success depended on list price inflation and rebate-driven formulary placement, a strategy that gave PBMs significant pricing leverage. As regulatory pressure forces PBMs away from rebate-dependent models toward transparent, net-price-based competition, Pfizer's $22.7 billion Humira franchise faces biosimilar competition without the formulary protection that previously sustained its market position. It's an open question how Pfizer will respond to the erosion of one of its critical sources of profit. Source: drugchannels.net/2026/04/the-bi…